Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial

Dongyang Liu, Ying Du, Xueting Yao, Yudong Wei, Jixiang Zhu, Cheng Cui, Hong Zhou, Min Xu, Haiyan Li, Linong Ji, Dongyang Liu, Ying Du, Xueting Yao, Yudong Wei, Jixiang Zhu, Cheng Cui, Hong Zhou, Min Xu, Haiyan Li, Linong Ji

Abstract

Background: PB-201, a partial, pancreas/liver-dual glucokinase activator, showed good tolerance and glycaemic effects in multinational studies. This study determined its optimal dose, safety, pharmacokinetics, and pharmacodynamics in Chinese patients with type 2 diabetes.

Methods: In this double-blind, randomised, four-period, crossover, phase 1 trial in China, conducted at the Peking University Third Hospital, adult patients with drug-naive type 2 diabetes were randomised (1:1:1:1) to four sequence groups using a computer-generated randomisation table. In each period, they received oral placebo or PB-201 (50+50, 100+50, or 100+100 mg split doses) for 7 days. Investigators and patients were masked to treatment assignment. The primary endpoints were safety and pharmacokinetics. Continuous glucose monitoring was used to delineate the glucose excursion profile. Trial registration number: NCT03973515.

Findings: Between August 27, 2019 and December 19, 2019, 16 patients were randomised. PB-201 showed a dose-proportional pharmacokinetic profile without apparent accumulation in the body and induced dose-dependent lowering of blood glucose. PB-201 at 50+50, 100+50, and 100+100 mg increased mean time in range (49·210% [standard deviation 27], 56·130% [25], and 63·330% [20] with three doses, respectively) versus placebo (49·380% [27]) and reduced estimated glycated haemoglobin from baseline (-0·5445% [1·654], -1·063% [1·236], and -1·888% [1·381] vs -0·581% [1·200]). Fifteen patients (93·8%) had treatment-emergent adverse events, which were mild. No patients had hypoglycaemia with venous/capillary glucose <3·9 mmol/L or nocturnal hypoglycaemia.

Interpretation: PB-201 100 mg twice daily is identified as the optimal dose, which shows promising glucose-lowering effects and low risks of hypoglycaemia and other side effects. Further investigation of PB-201 100 mg twice daily in confirmatory trials is warranted.

Funding: PegBio.

Keywords: Continuous glucose monitoring; Glucokinase activator PB-201; Type 2 diabetes.

Conflict of interest statement

YD and MX are employees of PegBio, and HZ is an ex-employee of PegBio. LJ has received fees for lecture presentations from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis and Takeda; consulting fees from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis and Takeda; and grants/research support from AstraZeneca, Bristol-Myers Squibb, Merck, Novartis and Sanofi-Aventis. All other authors declare no competing interests.

© 2021 The Author(s).

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Dose-normalised plasma PB-201 concentration–time profiles on days 1 and 7 Geometric mean (coefficient of variation) of dose-normalised plasma concentration of PB-201 versus time curves on day 1 (A) and day 7 (B) on a logarithmic scale.
Figure 3
Figure 3
CGM profiles of patients on placebo or PB-201 (A) Daily blood glucose dynamics measured by CGM. Solid lines represent mean values of glucose, and dotted lines represent the first and third quantiles. (B) Percentages of TIR, TBR, and TAR. CGM=continuous glucose monitoring. TAR=time above range. TBR=time below range. TIR=time in range.

References

    1. American Diabetes Association. 6 Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66–S76.
    1. American Diabetes Association. 9 Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
    1. Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013;13:602.
    1. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33(3):501–506.
    1. Matschinsky FM, Wilson DF. The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of Langerhans. Front Physiol. 2019;10:148.
    1. Klein KR, Freeman JLR, Dunn I, et al. The SimpliciT1 Study: a randomized, double-blind, placebo-controlled phase 1b/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Care. 2021;44(4):960–968.
    1. Vella A, Freeman JLR, Dunn I, Keller K, Buse JB, Valcarce C. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. 2019;11(475):eaau3441.
    1. Zhu D, Gan S, Liu Y, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6(8):627–636.
    1. Zheng S, Shao F, Ding Y, et al. Safety, pharmacokinetics, and pharmacodynamics of globalagliatin, a glucokinase activator, in Chinese patients with type 2 diabetes mellitus: a randomized, phase Ib, 28-day ascending dose study. Clin Drug Investig. 2020;40(12):1155–1166.
    1. Amin NB, Aggarwal N, Pall D, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015;17(8):751–759.
    1. Denney WS, Denham DS, Riggs MR, Amin NB. Glycemic effect and safety of a systemic, partial glucokinase activator, PF-04937319, in patients with type 2 diabetes mellitus inadequately controlled on metformin-a randomized, crossover, active-controlled study. Clin Pharmacol Drug Dev. 2016;5(6):517–527.
    1. Katz L, Manamley N, Snyder WJ, et al. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(2):191–195.
    1. Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011;34(12):2560–2566.
    1. De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol. 2013;168(2):339–353.
    1. Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2013;15(8):750–759.
    1. Pfefferkorn JA, Guzman-Perez A, Oates PJ, et al. Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-(5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. MedChemComm. 2011;2(9):828–839.
    1. Borzilleri KA, Pfefferkorn JA, Guzman-Perez A, et al. Optimizing glucokinase activator binding kinetics to lower in vivo hypoglycemia risk. MedChemComm. 2014;5(6):802–807.
    1. World Health Organization . World Health Organization; Geneva: 1999. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus.
    1. Society CD. Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition) Chinese Journal of Practical Internal Medicine. 2018;38(4):292–344.
    1. Sharma R, Litchfield J, Atkinson K, et al. Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metab Dispos. 2014;42(11):1926–1939.
    1. Guidelines for clinical trials of anti-diabetic agents and biologics. (accessed 24 December 2020).
    1. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–1603.
    1. Sayed A, Alyafei F, De Sanctis V, Soliman A, Elgamal M. Translating the HbA1c assay into estimated average glucose values in children and adolescents with type 1 diabetes mellitus. Acta Biomed. 2018;89(S5):22–26.
    1. Ji L, Guo X, Guo L, Ren Q, Yu N, Zhang J. A Multicenter Evaluation of the Performance and Usability of a Novel Glucose Monitoring System in Chinese Adults With Diabetes. J Diabetes Sci Technol. 2017;11(2):290–295.
    1. Guidelines for clinical pharmacokinetic studies. Center for Drug Evaluation of China National Medical Products Administration. (accessed 24 December 2020).
    1. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278–1283.
    1. Diao H, Yu X, Li C, Guo Y, Shen B, Zhao W. The effects and safety of activators of glucokinase versus placebo in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Endocr J. 2021;68(2):189–194.
    1. Galindo RJ, Migdal AL, Davis GM, et al. Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen. Diabetes Care. 2020;43(11):2730–2735.
    1. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol. 2019;13(4):614–626.
    1. Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21(2):81–85.
    1. Kiyosue A, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(10):923–930.
    1. Fujimoto K, Shibayama Y, Yamaguchi E, Honjo S, Hamasaki A, Hamamoto Y. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: a randomized cross-over trial. J Diabetes. 2018;10(8):675–682.
    1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–1310.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever